Status:
COMPLETED
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
MALE
18-75 years
Phase:
PHASE3
Brief Summary
The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate ...
Eligibility Criteria
Inclusion
- Histologically confirmed prostate cancer
- Locally advanced prostate cancer patients suitable for Casodex 150 mg monotherapy
Exclusion
- Age \> 75 yrs
- No metastatic disease (M1).
- No presence of gynaecomastia and/or mastalgia at screening
- No therapy with medications able to provoke gynaecomastia and/or mastalgia within 6 months of trial entry.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00233610
Start Date
December 1 2003
End Date
October 1 2007
Last Update
January 27 2011
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bari, BA, Italy
2
Research Site
Bologna, BO, Italy
3
Research Site
Catania, CT, Italy
4
Research Site
Bagno a Ripoli, FI, Italy